Abstract
The earlier large multicentre trials in hypertensive patients addressed questions of whether mild to moderate hypertension should be treated and whether similar approaches would be effective in elderly hypertensive patients or those with isolated systolic hypertension, The research focus of recent trials has now shifted to how rather than whether such patients should be treated. Trials such as the Hypertension Optimal Treatment study attempted to discern optimal targets for long-term blood pressure control. Although unsuccessful in this primary aim, they have established the safety of aggressive blood pressure lowering to diastolic targets of less than 80 mmHg as well as the safety and efficacy of a calcium entry blocker as a first line antihypertensive approach, The Captopril Prevention Project study and Swedish Trial in Old Patients with Hypertension-P trial focussed on whether there might be specific antiatherosclerotic advantages of the newer agents (angiotensin converting enzyme inhibitors acid calcium entry blockers) over conventional therapy in comparison studies with beta blockers and diuretics, Similar efficacy for cardiovascular outcomes appears to be emerging for each of the major classes of drugs with the degree of blood pressure lowering of prime importance in cardiovascular disease prevention, Curr Opin Nephrol Hypertens 9:285-292. (C) 2000 Lippincott Williams & Wilkins.
Original language | English |
---|---|
Pages (from-to) | 285-292 |
Journal | Current Opinion in Nephrology and Hypertension |
Volume | 9 |
DOIs | |
Publication status | Published - 2000 |